Clinical Trial Update: Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant nivolumab in combination therapy for resectable non-small cell lung cancer across stages I–IIIa, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: University Hospital, Essen | Conditions: NSCLC Stage II, NSCLC, Stage IIIA | Phase 2 | Status: RECRUITING